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Context
New approaches are needed for malaria control where the burden has
remained high despite scaled up coverage of long-lasting insecticide-treated
nets (LLIN) and prompt access to artemisinin-based combination therapies
(ACTs).1 Bigira and colleagues evaluated three regimens for chemoprevention
of malaria in young children in eastern Uganda, in an area of very high year-
round malaria transmission and high resistance to antifolate drugs, including
sulfadoxine-pyrimethamine (SP) and sulfamethoxazole.
Methods
Children between 6 and 24 months of age were randomised to receive
daily trimethoprim-sulfamethoxazole (TS), monthly SP, monthly
dihydroartemisinin-piperaquine (DP) or no intervention. All study partici-
pants were given LLINs. Follow-up continued to 36 months of age. The
primary outcome was incidence of uncomplicated malaria, treated with
artemether-lumefantrine (AL).
Findings
Between 6 and 24 months of age, children without chemoprevention experi-
enced almost seven malaria episodes per person-year, despite apparently
high LLIN use. Monthly SP provided no protection against clinical malaria
and possibly increased incidence of moderate–severe anaemia: protective
efﬁcacy (PE) −70% (95% CI −184% to −2%). Daily TS reduced clinical
malaria by 28% (95% CI 7% to 44%) despite antifolate resistance. Monthly
DP reduced clinical malaria by 58% (95% CI 45% to 67%) and possibly mod-
erate–severe anaemia: PE 47% (95% CI 1% to 72%). Self-reported adherence
was high but the reliability of this was unclear. There were no signiﬁcant dif-
ferences in incidence of complicated malaria or hospitalisation, although
numbers were low. Between 24 and 36 months of age, children experienced
close to 11 episodes per person-year, regardless of prior intervention group.
Commentary
A 58% reduction in malaria incidence in an area of such high burden
reﬂects an important potential public health impact. However, efﬁcacy is
lower than expected given the regularity of dosing and the high efﬁcacy of
DP. Monthly DP given as directly observed therapy reduced clinical
malaria by 96% among Ugandan school children.2 This suggests adher-
ence to monthly DP was not optimal under trial conditions, which is a
concern. Lack of reliable information on adherence may also undermine
the ﬁnding that piperaquine did not affect the QTc interval, although other
studies have partly allayed these concerns.3 ACTs such as DP are not ideal
for chemoprevention because the artemisinin component is eliminated
rapidly, leaving the partner drug as monotherapy soon after administra-
tion. New regimens speciﬁcally for chemoprevention are needed.
Chemoprevention requires carefully supervised delivery. This is
because suboptimal adherence could accelerate development of resistance
to the drugs used, if either incomplete courses are taken, or drugs are not
readministered each month and concentrations fall below subtherapeutic
levels. However, in areas of very high incidence, drug pressure on ACTs
will be large even in the absence of chemoprevention: after the interven-
tion period, children received 11 courses of AL per person-year.
Well-administered chemoprevention may avoid these issues and help
prolong the life of ACTs used for treatment. Community-based health
workers may be one means to improve adherence, increase coverage
outside the context of a trial, and may be more cost-effective per dose
administered, as for monthly seasonal malaria chemoprevention.4
Implications for practice
Chemoprevention is currently recommended for children under 5 years
old in areas of high and seasonal malaria transmission and in infants in
areas with high malaria transmission and low SP resistance.5 6 Adapting
chemoprevention to areas with high, year-round transmission and/or
high SP resistance could have a substantial impact. Additional research
in this area is crucial to inform future changes in practice. Further studies
are needed to evaluate adherence and delivery, the safety and pharmaco-
kinetics of repeated treatments and selection for resistant parasites.
Despite exceptionally high transmission, the burden of clinical and
complicated malaria was higher in the postintervention period in this
study. Providing chemoprevention to a wider age range could potentially
increase impact further. If monthly chemoprevention is given for longer,
there may be more scope for rebound morbidity later in life, concerns
also faced by preventive approaches including malaria vaccines.
While it is unclear how widely year-round chemoprevention will be
appropriate, it will be most cost-effective in areas with very high incidence:
control policy needs to be tailored to local epidemiology. Focusing on fewer
areas may also limit the impact of chemoprevention on resistance. This will
require policymakers to have accurate and regularly updated information on
malaria epidemiology and drug resistance markers.
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